逸達生物科技 Foresee Pharmaceuticals Co., Ltd.

Press Release

Date
Title
2023-08-29
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI®, Extending Patent Protection to 2039
2023-07-25
Foresee Pharmaceuticals Selected for Late-Breaking Oral Presentation on its Aderamastat Phase 2 Study Results at the European Respiratory Society (ERS) International Congress 2023
2023-06-27
Foresee Pharmaceuticals Announces Completion of US$42.3 Million Financing
2023-06-21
Foresee Pharmaceuticals Presented Poster on MMP-12 inhibitor, FP-020, in Genetic Model of Sarcoidosis at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases
2023-06-16
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the WASOG 2023 International Conference on Sarcoidosis and Interstitial Lung Diseases (ILDs)
2023-04-17
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development
2023-04-04
Foresee announced the Primary Endpoint Results of FP-025 in an Allergic Asthma Phase 2a Trial
2022-05-31
Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization
2022-04-04
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
2022-02-23
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement

Total 29 ( 10 records per page )　　Previous　　Next　　Go page